Suppr超能文献

一种保留对侧食管的技术,用于限制胸部恶性肿瘤患者接受同期大剂量放疗和化疗时发生严重食管炎。

A Contralateral Esophagus-Sparing Technique to Limit Severe Esophagitis Associated With Concurrent High-Dose Radiation and Chemotherapy in Patients With Thoracic Malignancies.

机构信息

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

出版信息

Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):803-10. doi: 10.1016/j.ijrobp.2015.03.018. Epub 2015 Mar 25.

Abstract

PURPOSE

Severe (Radiation Therapy Oncology Group [RTOG] grade 3 or greater) esophagitis generally occurs in 15% to 25% of non-small cell lung cancer (NSCLC) patients undergoing concurrent chemotherapy and radiation therapy (CCRT), which may result in treatment breaks that compromise local tumor control and pose a barrier to dose escalation. Here, we report a novel contralateral esophagus-sparing technique (CEST) that uses intensity modulated radiation therapy (IMRT) to reduce the incidence of severe esophagitis.

METHODS AND MATERIALS

We reviewed consecutive patients with thoracic malignancies undergoing curative CCRT in whom CEST was used. The esophageal wall contralateral (CE) to the tumor was contoured as an avoidance structure, and IMRT was used to guide a rapid dose falloff gradient beyond the target volume in close proximity to the esophagus. Esophagitis was recorded based on the RTOG acute toxicity grading system.

RESULTS

We identified 20 consecutive patients treated with CCRT of at least 63 Gy in whom there was gross tumor within 1 cm of the esophagus. The median radiation dose was 70.2 Gy (range, 63-72.15 Gy). In all patients, ≥99% of the planning and internal target volumes was covered by ≥90% and 100% of prescription dose, respectively. Strikingly, no patient experienced grade ≥3 esophagitis (95% confidence limits, 0%-16%) despite the high total doses delivered. The median maximum dose, V45, and V55 of the CE were 60.7 Gy, 2.1 cc, and 0.4 cc, respectively, indicating effective esophagus cross-section sparing by CEST.

CONCLUSION

We report a simple yet effective method to avoid exposing the entire esophagus cross-section to high doses. By using proposed CE dose constraints of V45 <2.5 cc and V55 <0.5 cc, CEST may improve the esophagus toxicity profile in thoracic cancer patients receiving CCRT even at doses above the standard 60- to 63-Gy levels. Prospective testing of CEST is warranted.

摘要

目的

在接受同步放化疗(CCRT)的非小细胞肺癌(NSCLC)患者中,严重(放射治疗肿瘤学组[RTOG] 3 级或更高级别)食管炎的发生率一般为 15%至 25%,这可能导致治疗中断,从而影响局部肿瘤控制并阻碍剂量升级。在这里,我们报告了一种新的对侧食管保护技术(CEST),该技术使用调强放疗(IMRT)来降低严重食管炎的发生率。

方法和材料

我们回顾了连续接受根治性 CCRT 的胸部恶性肿瘤患者的病例,这些患者使用了 CEST。肿瘤对侧(CE)食管被描绘为避照结构,IMRT 用于引导靶体积附近的食管快速剂量陡降梯度。根据 RTOG 急性毒性分级系统记录食管炎。

结果

我们确定了 20 例接受至少 63 Gy CCRT 的连续患者,这些患者的肿瘤位于食管 1 厘米以内。中位放射剂量为 70.2 Gy(范围 63-72.15 Gy)。在所有患者中,≥99%的计划和内部靶体积分别被≥90%和 100%的处方剂量覆盖。值得注意的是,尽管总剂量较高,但没有患者出现≥3 级食管炎(95%置信区间,0%-16%)。CE 的中位最大剂量、V45 和 V55 分别为 60.7 Gy、2.1 cc 和 0.4 cc,表明 CEST 有效保护了食管的横截面积。

结论

我们报告了一种简单而有效的方法,可以避免将整个食管横截面积暴露于高剂量下。通过使用建议的 CE 剂量限制,即 V45<2.5 cc 和 V55<0.5 cc,CEST 可能会改善接受 CCRT 的胸部癌症患者的食管毒性谱,即使剂量高于标准的 60-63 Gy 水平。有必要进行 CEST 的前瞻性测试。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验